Cargando…
The SR-B1 Receptor as a Potential Target for Treating Glioblastoma
PURPOSE: The goal of these studies was to provide proof of concept for a novel targeted therapy for Glioblastoma Multiforme (GBM). Methods. These studies involve the evaluation of reconstituted high density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for the drug, mammalian Target of R...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6583082/ https://www.ncbi.nlm.nih.gov/pubmed/31275377 http://dx.doi.org/10.1155/2019/1805841 |
_version_ | 1783428433307500544 |
---|---|
author | Berney, Ethan Sabnis, Nirupama Panchoo, Marlyn Raut, Sangram Dickerman, Rob Lacko, Andras G. |
author_facet | Berney, Ethan Sabnis, Nirupama Panchoo, Marlyn Raut, Sangram Dickerman, Rob Lacko, Andras G. |
author_sort | Berney, Ethan |
collection | PubMed |
description | PURPOSE: The goal of these studies was to provide proof of concept for a novel targeted therapy for Glioblastoma Multiforme (GBM). Methods. These studies involve the evaluation of reconstituted high density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for the drug, mammalian Target of Rapamycin (mTOR) inhibitor Everolimus (EVR) to GBM cells. Cytotoxicity studies and assessment of downstream effects, including apoptosis, migration, and cell cycle events, were probed, in relation to the expression of scavenger receptor B type 1 (SR-B1) by GBM cells. RESULTS: Findings from cytotoxicity studies indicate that the rHDL/EVR formulation was 185 times more potent than free EVR against high SR-B1 expressing cell line (LN 229). Cell cycle analysis revealed that rHDL/EVR treated LN229 cells had a 5.8 times higher apoptotic cell population than those treated with EVR. The sensitivity of GBM cells to EVR treatment was strongly correlated with SR-B1 expression. CONCLUSIONS: These studies present strong proof of concept regarding the efficacy of delivering EVR and likely other agents, via a biocompatible transport system, targeted to the SR-B1 receptor that is upregulated in most cancers, including GBM. Targeting the SR-B1 receptor could thus lead to effective personalized therapy of GBM. |
format | Online Article Text |
id | pubmed-6583082 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-65830822019-07-03 The SR-B1 Receptor as a Potential Target for Treating Glioblastoma Berney, Ethan Sabnis, Nirupama Panchoo, Marlyn Raut, Sangram Dickerman, Rob Lacko, Andras G. J Oncol Research Article PURPOSE: The goal of these studies was to provide proof of concept for a novel targeted therapy for Glioblastoma Multiforme (GBM). Methods. These studies involve the evaluation of reconstituted high density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for the drug, mammalian Target of Rapamycin (mTOR) inhibitor Everolimus (EVR) to GBM cells. Cytotoxicity studies and assessment of downstream effects, including apoptosis, migration, and cell cycle events, were probed, in relation to the expression of scavenger receptor B type 1 (SR-B1) by GBM cells. RESULTS: Findings from cytotoxicity studies indicate that the rHDL/EVR formulation was 185 times more potent than free EVR against high SR-B1 expressing cell line (LN 229). Cell cycle analysis revealed that rHDL/EVR treated LN229 cells had a 5.8 times higher apoptotic cell population than those treated with EVR. The sensitivity of GBM cells to EVR treatment was strongly correlated with SR-B1 expression. CONCLUSIONS: These studies present strong proof of concept regarding the efficacy of delivering EVR and likely other agents, via a biocompatible transport system, targeted to the SR-B1 receptor that is upregulated in most cancers, including GBM. Targeting the SR-B1 receptor could thus lead to effective personalized therapy of GBM. Hindawi 2019-06-03 /pmc/articles/PMC6583082/ /pubmed/31275377 http://dx.doi.org/10.1155/2019/1805841 Text en Copyright © 2019 Ethan Berney et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Berney, Ethan Sabnis, Nirupama Panchoo, Marlyn Raut, Sangram Dickerman, Rob Lacko, Andras G. The SR-B1 Receptor as a Potential Target for Treating Glioblastoma |
title | The SR-B1 Receptor as a Potential Target for Treating Glioblastoma |
title_full | The SR-B1 Receptor as a Potential Target for Treating Glioblastoma |
title_fullStr | The SR-B1 Receptor as a Potential Target for Treating Glioblastoma |
title_full_unstemmed | The SR-B1 Receptor as a Potential Target for Treating Glioblastoma |
title_short | The SR-B1 Receptor as a Potential Target for Treating Glioblastoma |
title_sort | sr-b1 receptor as a potential target for treating glioblastoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6583082/ https://www.ncbi.nlm.nih.gov/pubmed/31275377 http://dx.doi.org/10.1155/2019/1805841 |
work_keys_str_mv | AT berneyethan thesrb1receptorasapotentialtargetfortreatingglioblastoma AT sabnisnirupama thesrb1receptorasapotentialtargetfortreatingglioblastoma AT panchoomarlyn thesrb1receptorasapotentialtargetfortreatingglioblastoma AT rautsangram thesrb1receptorasapotentialtargetfortreatingglioblastoma AT dickermanrob thesrb1receptorasapotentialtargetfortreatingglioblastoma AT lackoandrasg thesrb1receptorasapotentialtargetfortreatingglioblastoma AT berneyethan srb1receptorasapotentialtargetfortreatingglioblastoma AT sabnisnirupama srb1receptorasapotentialtargetfortreatingglioblastoma AT panchoomarlyn srb1receptorasapotentialtargetfortreatingglioblastoma AT rautsangram srb1receptorasapotentialtargetfortreatingglioblastoma AT dickermanrob srb1receptorasapotentialtargetfortreatingglioblastoma AT lackoandrasg srb1receptorasapotentialtargetfortreatingglioblastoma |